This review discusses the evidence in support of the use of daclatasvir (Daklinza®) for the treatment of chronic hepatitis C virus (HCV) infection, with a focus on genotype 1 and 3 infection and in human immunodeficiency virus (HIV) co-infection.
Independent commentary by Prof. Alexander Thompson. Prof. Thompson is Director of Gastroenterology at St. Vincent's Hospital, Melbourne. He is also a Neil-Hamilton Fairley NHMRC Research Fellow at the University of Melbourne, and consultant to the Victorian Infectious Diseases Reference Laboratory (VIDRL).
Please login below to download this issue (PDF)